8-quinoline sulfonamide compound and application thereof

A quinoline sulfonamide and compound technology, applied in the field of medicinal chemistry, can solve problems such as incomplete remission

Pending Publication Date: 2022-08-09
ANHUI RUBIOX VISION BIOTECH
0 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0004] Drugs currently approved by the FDA to treat RA often provide tempora...
View more

Abstract

The invention relates to an 8-quinoline sulfonamide compound and application thereof. R is hydrogen, 4-methyl, 4-isopropyl, 2, 4, 6-triisopropyl, 4-tert-butyl, 2, 4-dimethoxy, 3, 4-dimethoxy, 2-fluorine, 3-fluorine, 4-fluorine, 2, 6-difluorine, 2-trifluoromethyl, 3-trifluoromethyl, 4-trifluoromethyl, 3, 5-di-trifluoromethyl, 2-trifluoromethoxy, 4-trifluoromethoxy, 2-chlorine, 4-chlorine, 2, 6-dichloro, 3, 4-dimethoxy, 4-tert-butyl, 2, 4-dimethoxy, 3, 4-dimethoxy, 4-tert-butyl, 2, 4-dimethoxy, 3, 4-dimethoxy, 2-trifluoromethyl, 3, 5-di-trifluoromethyl, 2-trifluoromethoxy, 4-trifluoromethoxy, 2-chlorine, 4-chlorine, 2, 6-dichloro, 3, the compound is any one of 2, 5-dichloro, 2-bromo, 3-bromo, 4-bromo, 3-bromine-5-trifluoromethyl and the like. The compound has an inhibiting effect on generation of macrophage NO stimulated by LPS, can reduce release of inflammation-related cytokines and expression of protein, and has the potential to be developed into a medicine for treating inflammatory diseases.

Application Domain

Organic chemistryAntipyretic +4

Technology Topic

SulfonilamideTrifluoromethyl +10

Image

  • 8-quinoline sulfonamide compound and application thereof
  • 8-quinoline sulfonamide compound and application thereof
  • 8-quinoline sulfonamide compound and application thereof

Examples

  • Experimental program(35)

Example Embodiment

[0038] Example 1
[0039] Synthesis of compound f1:
[0040]
[0041] Compound d (299 mg, 1 mM) was dissolved in 2 mL of pyridine, and then benzenesulfonyl chloride (substituent R was hydrogen) (176 mg, 1 mM) was added to react at room temperature for 8-12 h. The progress of the reaction was checked by TLC. After the reaction was completed, the reaction solvent was removed. Compound f1 was obtained by ethyl acetate:petroleum ether (1:4) column chromatography to obtain compound f1, which was a white solid with a yield of 68%.
[0042] 1 H NMR (500MHz, DMSO-d 6 )δ10.09(d,J=28.9Hz,2H),9.11(dd,J=4.3,1.8Hz,1H),8.50(d,J=8.4Hz,1H),8.28(dd,J=15.5,7.1 Hz, 2H), 7.79(d, J=7.0Hz, 1H), 7.60(t, J=7.7Hz, 1H), 7.54(t, J=7.4Hz, 2H), 7.50(d, J=7.1Hz, 2H), 7.40(t, J=7.8Hz, 2H), 7.06(s, 1H), 6.89(t, J=8.1Hz, 1H), 6.69(d, J=8.1Hz, 1H), 6.54(d, J=8.0Hz, 1H); 13 C NMR (126MHz, DMSO) δ 151.38, 142.61, 139.27, 138.10, 136.84, 134.97, 134.14, 132.69, 132.10, 129.23, 128.93, 127.67, 126.37, 125.51, 122.54, 115.969, 115.51

Example Embodiment

[0043] Example 2
[0044] Synthesis of compound f2:
[0045]
[0046] The method is the same as in Example 1, except that the substituent R in the benzenesulfonyl chloride is 4-methyl, and a white solid, namely compound f2, is obtained in a yield of 70%.
[0047] 1 H NMR (500MHz, DMSO-d 6 )δ10.31(s, 2H), 9.33(dd, J=4.2, 1.9Hz, 1H), 8.72(d, J=8.2Hz, 1H), 8.51(dd, J=23.6, 7.9Hz, 2H), 7.98–7.86(m, 2H), 7.61(d, J=8.3Hz, 2H), 7.40(d, J=7.9Hz, 2H), 7.28(s, 1H), 7.10(t, J=8.1Hz, 1H) ), 6.89(d, J=8.1Hz, 1H), 6.74(d, J=8.0Hz, 1H), 2.50(s, 3H); 13 C NMR (126MHz, DMSO) δ 151.46, 143.07, 142.67, 138.50, 138.31, 136.90, 136.44, 135.00, 134.21, 132.23, 129.44, 128.38, 126.53, 125.57, 122.61, 20.617, 110.61, 115.61.

Example Embodiment

[0048] Example 3
[0049] Synthesis of compound f3:
[0050]
[0051] The method is the same as in Example 1, except that the substituent R in the benzenesulfonyl chloride is 4-isopropyl, and a white solid, namely compound f3, is obtained in a yield of 76%.
[0052] 1 H NMR (500MHz, DMSO-d 6 )δ10.15(s, 2H), 9.12(dd, J=4.2, 1.8Hz, 1H), 8.52(dd, J=8.4, 1.8Hz, 1H), 8.33(dd, J=7.3, 1.5Hz, 1H) ),8.28(dd,J=8.3,1.4Hz,1H),7.75–7.66(m,2H),7.46(d,J=8.5Hz,2H),7.27(d,J=8.5Hz,2H),7.10 (t, J=2.1Hz, 1H), 6.88 (t, J=8.1Hz, 1H), 6.67 (dd, J=8.1, 1.2Hz, 1H), 6.53 (dd, J=8.1, 1.2Hz, 1H) ,2.89(p,J=6.9Hz,1H),1.14(d,J=6.9Hz,7H); 13 C NMR (126MHz, DMSO) δ 153.51, 151.48, 142.71, 138.56, 138.37, 136.95, 135.06, 134.24, 132.25, 129.35, 128.41, 126.98, 126.66, 125.60, 122.63, 3.3.2.9,2,17

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products